|
?:abstract
|
-
It is essential to know whether COVID-19 patients have a history of cerebrovascular disease, as it may be predictive of prognosis and useful for allocation of limited medical resources This meta-analysis was performed to assess the incidence of cerebrovascular disease as a comorbidity in COVID-19 patients The PubMed, Cochrane Library, Embase, CNKI, WFSD, and VIP databases were systematically searched The pooled analysis of relevant data was conducted using RevMan 5 3 software The primary outcome was incidence of cerebrovascular disease as a comorbidity Forty-seven studies involving 16,143 COVID-19 patients were included in this analysis The incidences of a history of cerebrovascular disease and hypertension in COVID-19 patients were estimated to be 3 0% (95% CI, 2 0%-4 0%;P<0 00001) and 23 0% (95% CI, 16 0%-29 0%;P<0 00001), respectively The incidence of dizziness/headache as the first symptom in COVID-19 patients was estimated to be 14 0% (95% CI, 8 0%-20 0%;P<0 00001) Subgroup analyses indicated that country, sex ratio, and sample size are potential influencing factors affecting the incidences of cerebrovascular disease, hypertension, and dizziness/headache These findings suggest that cerebrovascular disease is an underlying comorbidity among patients with COVID-19 In addition, patients experiencing dizziness/headache as the first symptom of COVID-19 should receive a neurological examination
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}